Paul J. Hastings submitted an initial statement of beneficial ownership with the SEC on November 10, 2026, in connection with an event date of November 3, 2026, disclosing his status as a director of Azora Therapeutics, Inc. (DE), listed on NASDAQ:AZR.

Key Highlights

  • Reporting Person: Paul J. Hastings, identified as a director of Azora Therapeutics, Inc. (DE)
  • Event Date: The date of event requiring the statement was November 3, 2026
  • Filing Date: The statement was filed on November 10, 2026
  • No Securities Held: The filing states "No securities are beneficially owned" in either Table I or Table II
  • Issuer: Azora Therapeutics, Inc. (DE), trading under ticker AZR on NASDAQ
  • Signed By: Matthew Davidson, acting as Attorney-in-Fact under a Power of Attorney (Exhibit 24)

Hastings Reports No Beneficial Ownership Upon Joining Azora Therapeutics Board

According to the filing, Paul J. Hastings submitted an initial statement of beneficial ownership required under Section 16(a) of the Securities Exchange Act of 1934. The filing was submitted individually, as a single reporting person, and identifies Hastings solely in the capacity of director. His address is listed as care of Azora Therapeutics, Inc., located at 16501 Ventura Blvd., Suite 400, Encino, California 91436.

As disclosed in the filing, both Table I, covering non-derivative securities, and Table II, covering derivative securities such as puts, calls, warrants, options, and convertible securities, contain no entries. The filing explicitly states that "No securities are beneficially owned." This indicates that at the time of the triggering event on November 3, 2026, Hastings held no direct or indirect beneficial ownership in any class of Azora Therapeutics securities, whether equity or derivative instruments.

The statement was signed by Matthew Davidson as Attorney-in-Fact on November 10, 2026, pursuant to the Power of Attorney attached as Exhibit 24 to the filing. Azora Therapeutics, Inc. (DE) is the issuer named in the filing, with ticker symbol AZR on NASDAQ. The filing was submitted on behalf of one reporting person only, as indicated by the checked box for "Form filed by One Reporting Person."

What Was Disclosed

Paul J. Hastings, a newly identified director of Azora Therapeutics, Inc. (DE) on NASDAQ:AZR, filed an initial beneficial ownership statement dated November 10, 2026, covering a November 3, 2026 event date, reporting no beneficial ownership of any securities of the company.